» Authors » Tripti Shrivastava

Tripti Shrivastava

Explore the profile of Tripti Shrivastava including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 49
Citations 565
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Qureshi M, Shrivastava T, Sharath H, Kaur G
Cureus . 2024 Oct; 16(9):e69431. PMID: 39411623
Educational institutions must change to create a learning ecosystem that prioritizes skills crucial for the 21st-century learners in the current global context that is quickly evolving. With an emphasis on...
2.
Jaiswal S, Shrivastava T
Cureus . 2024 May; 16(4):e59104. PMID: 38803727
Myasthenia gravis (MG) is an autoimmune illness characterized by autoantibodies against the acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), and an increasing number of extra postsynaptic proteins. Pathogenic autoantibodies reduce...
3.
Qureshi M, Shrivastava T, Mishra V, Mishra G
Cureus . 2024 Apr; 16(3):e56937. PMID: 38665749
The Triple "O" model in educational research, meaning the Objectives, Operations, and Outcomes model, is a plan to dive into how research works. Objectives are the reasons for this research,...
4.
Jaiswal A, Shrivastava T
Cureus . 2024 Apr; 16(3):e56214. PMID: 38618417
In this article, we discuss the ethics of veganism by looking at the moral implications of having a vegan diet or plant-based diet. Veganism is a way of diet that...
5.
Nandy P, Shrivastava T
Cureus . 2024 Feb; 16(1):e52727. PMID: 38384651
A suitable portion of the total population still suffers through acne vulgaris, a widespread dermatological illness that mostly affects teens and young adults. Although acne is typically considered to be...
6.
Jankar A, Shrivastava T
Cureus . 2023 Feb; 15(1):e34027. PMID: 36814731
Ulcerative colitis (UC) causes diffuse friability and superficial wall degeneration that is accompanied by bleeding. UC, now recognized as a global illness, affects millions of people globally. The most effective...
7.
Parray H, Narayanan N, Garg S, Rizvi Z, Shrivastava T, Kushwaha S, et al.
PLoS Pathog . 2022 Dec; 18(12):e1010994. PMID: 36508467
The emergence of new variants of SARS-CoV-2 necessitates unremitting efforts to discover novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb named P4A2 that can neutralize all...
8.
Binayke A, Zaheer A, Dandotiya J, Gupta S, Mani S, Tripathy M, et al.
Vaccines (Basel) . 2022 Oct; 10(10). PMID: 36298628
The underlying factors contributing to the evolution of SARS-CoV-2-specific T cell responses during COVID-19 infection remain unidentified. To address this, we characterized innate and adaptive immune responses with metabolomic profiling...
9.
Kumar C, Singh B, Rizvi Z, Parray H, Verma J, Ghosh S, et al.
ACS Infect Dis . 2022 Sep; 8(10):2119-2132. PMID: 36129193
The engineering of virus-like particles (VLPs) is a viable strategy for the development of vaccines and for the identification of therapeutic targets without using live viruses. Here, we report the...
10.
Agarwal S, Kaur S, Asuru T, Joshi G, Shrimali N, Singh A, et al.
Clin Transl Med . 2022 Sep; 12(9):e1041. PMID: 36121179
No abstract available.